top of page
BRIDGE
PHASE II TRIAL OF DURVALUMAB AND CHEMOTHERAPY INDUCTION FOLLOWED BY DURVALUMAB AND RADIOTHERAPY IN LARGE VOLUME STAGE III NSCLC
CLINICAL TRIAL DETAILS
STAGE III A-B-C (ACCORDING TO VERSION 8 OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STAGING MANUAL IN THORACIC ONCOLOGY) NSCLC PATIENTS NOT ELIGIBLE FOR SURGERY OR CONCURRENT CHEMORADIATION AT DIAGNOSIS BECAUSE OF LARGE TUMOR VOLUMES. THIS IS A MULTICENTRIC, OPEN LABEL, SINGLE ARM, SIMON 2 STAGES PHASE 2 TRIAL.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
NSCLC
3
65
II
Spain, France, Italy
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
-----
BLOG ARTICLES RELATED
-----
TRIAL SITES
Vall d'Hebron Institute of Oncology (VHIO) (Spain)
Gustave Roussy (France)
Institute Tumori Mario Negrini (Italy)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page